跳至主要内容
临床试验/EUCTR2007-001921-86-DE
EUCTR2007-001921-86-DE进行中(未招募)不适用

A double-blind, placebo-controlled, parallel-group, multi-center study to investigate the effect of Omacor? (n-3 PUFA) on lipid parameters in HIV infected patients treated with HAART

Solvay Pharmaceuticals GmbH0 个研究点目标入组 65 人开始时间: 2007年5月11日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
65

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Subjects = 18 years of age
  • 2. Documented HIV-infection
  • 3. On HAART for the last 3 months
  • 4. Written informed consent
  • 5. Plasma triglycerides values between 200 mg/100 ml and 1000 mg/100 ml
  • 6. Fibrate treatment that has been ongoing for at least 3 months prior to randomization is considered acceptable
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Age below 18 years
  • 2. Other malign disease
  • 3. Subjects assessed to be not compliant with study
  • 4. Females must be non-lactating and either be of non-childbearing potential (i.e. sterilized via hysterectomy or bilateral tubal-ligation or at least one year postmenopausal) or if of childbearing potential, agree to practice effective barrier contraceptive methods, use an intrauterine device (IUD) or use birth-control pills or equivalent injectable contraceptive. The subjects must have been practicing the selected method of birth control for at least 3 months prior to visit 1.
  • 5. Subjects taking fish oil capsules 8 weeks prior to inclusion in this study
  • 6. Known allergy to fish oil or soy
  • 7. Treatment with statins which can not be stopped
  • 8. Treatment with oral anti-coagulants

研究者

相似试验

进行中(未招募)
1 期
A double-blind, placebo-controlled, parallel-group, multi-center study to investigate the effect of Omacor? (n-3 PUFA) on lipid parameters in HIV infected patients treated with HAARTHAART-induced hypertriglyeridemia in HIV infected subjectsMedDRA version: 9.1 Level: LLT Classification code 10020869 Term: Hypertriglyceridaemia
EUCTR2007-001921-86-GBSolvay Pharmaceuticals GmbH65
进行中(未招募)
1 期
A safety and efficacy study of pregabalin in children 4-16 years of age with partial onset seizurepartial onset seizuresMedDRA version: 14.1Level: LLTClassification code 10034089Term: Partial seizures NOSSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2010-020852-79-ITPFIZER INC.153
进行中(未招募)
不适用
A study to determine the safety, tolerability and efficacy of AMAP102 compared to placebo in patients with osteoarthritisMedDRA version: 16.1Level: LLTClassification code 10019115Term: Hand osteoarthritisSystem Organ Class: 100000004859MedDRA version: 16.1Level: LLTClassification code 10023476Term: Knee osteoarthritisSystem Organ Class: 100000004859Osteoarthritis
EUCTR2012-001769-34-SEAnaMar AB120
进行中(未招募)
不适用
A study to determine the safety, tolerability and efficacy of AMAP102 compared to placebo in patients with osteoarthritisOsteoarthritis
EUCTR2012-001769-34-DEAnaMar AB120
进行中(未招募)
不适用
A double-blind, placebo-controlled, parallel group, proof of concept trial to assess the tolerabiltiy, safety and efficacy of rotigotine nasal spray for the acute treatment of 'off' symptoms in subjects with advanced-stage, idiopathic Parkinson's diseaseadvanced-stage, idiopathic Parkinson's diseaseMedDRA version: 8.1Level: LLTClassification code 10061536
EUCTR2005-004290-19-DESchwarz Biosciences GmbH100
A double-blind, placebo-controlled, parallel-group,... | 临床试验